Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors

The clinical profiles and outcomes of patients with neurotrophic tropomyosin receptor kinase fusion-positive (NTRK(+)) solid tumors receiving standard of care other than tropomyosin receptor kinase inhibitor (TRKi) targeted therapy have not been well documented. Here, we describe the clinical charac...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibar, Derrek P., Demetri, George D., Peters, Solange, Davies, Jessica, Humblet, Olivier, Maund, Sophia L., Perez, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359555/
https://www.ncbi.nlm.nih.gov/pubmed/35939431
http://dx.doi.org/10.1371/journal.pone.0270571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359555/
https://www.ncbi.nlm.nih.gov/pubmed/35939431
http://dx.doi.org/10.1371/journal.pone.0270571

Ejemplares similares